XENT

AcronymDefinition
XENTXML Enriched N-Triples
References in periodicals archive ?
* Intersect ENT, Inc.(NASDAQ: XENT) fell 18% to close at $16.50 after the company reported worse-than-expected Q2 EPS and sales results.
Leerink analyst Richard Newitter attributes the underperformance today in shares of Intersect ENT (XENT) to Regeneron's (REGN) positive Phase 3 Dupixent data for chronic rhinosinusitis with nasal polyps.
(NASDAQ: XENT) has received approval from the US Food and Drug Administration for an expanded indication for the Propel mini steroid releasing sinus implant to treat patients undergoing frontal sinus surgery, the company said.
* Intersect ENT, Inc.(NASDAQ: XENT) fell 18.1% to $16.48 after the company reported worse-than-expected Q2 EPS and sales results.
* Piper Jaffray downgraded the previous rating for Intersect ENT Inc (NASDAQ: XENT) from Overweight to Neutral.
(NASDAQ: XENT) has appointed Chas McKhann as chief commercial officer, the company said.
(NASDAQ: XENT) shares plummeted 13.3% today to $17.45.
(NYSE: NVRO) has appointed US-based health care equipment company Intersect ENT (NASDAQ: XENT) president and chief executive officer Lisa Earnhardt to its board of directors, the company said on Tuesday.
* Intersect ENT (NASDAQ: XENT) shares set a new yearly low of $17.50 this morning.
(NASDAQ: XENT) has launched an underwritten public offering of 3m shares of its common stock to be sold by the company, the company said on Monday.